Medical technology firm Boston Scientific has commercially introduced its Precision Novi Spinal Cord Stimulator (SCS) system in Europe.
The 16-contact primary cell device has received CE mark approval to treat chronic pain and is claimed to be the smallest primary cell device currently available in the market.
Boston Scientific neuromodulation president Maulik Nanavaty said: "We are excited to expand upon our range of therapeutic solutions for patients suffering from chronic pain.
"The Precision Novi System brings the power of our Illumina 3D Algorithm to the more than sixty percent of SCS patients in Europe who are treated with primary cell therapy."
Featuring Illumina 3D Software, the Precision Novi allows physicians to target pain precisely with point-and-click simplicity.
The Precision Novi Illumina 3D neural targeting software integrates three-dimensional lead location, in addition to the conductivity of the spinal cord and surrounding tissue.
The point-and-click technology is said to automatically calculate the optimal programming configuration to target the selected pain area.
Novi is a MultiWave platform that can deliver a variety of field shapes and waveforms with or without paresthesia, including burst and higher rate frequencies.
The Precision Novi SCS System is currently not available for sale in the US.